Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Adult accounting for % of the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immune DTaP Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, and Seqirus, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with price, sales, revenue and global market share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine from 2019 to 2022.
Chapter 3, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.
Chapter 13, 14, and 15, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Adult accounting for % of the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immune DTaP Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, and Seqirus, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- Immune DTaP Vaccine
- Therapy DTaP Vaccine
- Adult
- Pediatric
- Sanofi Pasteur
- GlaxoSmithKline
- Protein Sciences Corporation
- Novartis AG
- Seqirus
- Merck Sharp & Dohme Corp
- Astellas Pharma US
- Pfizer Inc
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co., Ltd
- AstraZeneca
- Emergent BioSolutions Inc
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with price, sales, revenue and global market share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine from 2019 to 2022.
Chapter 3, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.
Chapter 13, 14, and 15, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size & Forecast
1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume (2017-2028)
1.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2017-2028)
1.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity Analysis
1.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
1.6.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
1.6.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Protein Sciences Corporation
2.3.1 Protein Sciences Corporation Details
2.3.2 Protein Sciences Corporation Major Business
2.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Seqirus
2.5.1 Seqirus Details
2.5.2 Seqirus Major Business
2.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business
2.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Astellas Pharma US
2.7.1 Astellas Pharma US Details
2.7.2 Astellas Pharma US Major Business
2.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business
2.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business
2.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Lanzhou Institute of Biological Products Co., Ltd
2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
2.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business
2.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BREAKDOWN DATA BY MANUFACTURER
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.5 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
6.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
7.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
7.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
8.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
8.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
8.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
9.3.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
10.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
10.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.3.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
11.3.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Distributors
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size & Forecast
1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume (2017-2028)
1.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2017-2028)
1.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity Analysis
1.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
1.6.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
1.6.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Protein Sciences Corporation
2.3.1 Protein Sciences Corporation Details
2.3.2 Protein Sciences Corporation Major Business
2.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Seqirus
2.5.1 Seqirus Details
2.5.2 Seqirus Major Business
2.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business
2.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Astellas Pharma US
2.7.1 Astellas Pharma US Details
2.7.2 Astellas Pharma US Major Business
2.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business
2.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business
2.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Lanzhou Institute of Biological Products Co., Ltd
2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
2.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business
2.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BREAKDOWN DATA BY MANUFACTURER
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.5 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
6.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
7.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
7.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
8.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
8.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
8.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
9.3.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
10.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
10.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.3.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
11.3.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Distributors
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
LIST OF TABLES
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 6. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 10. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Protein Sciences Corporation Basic Information, Manufacturing Base and Competitors
Table 12. Protein Sciences Corporation Major Business
Table 13. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 14. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 16. Novartis AG Major Business
Table 17. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 18. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Seqirus Basic Information, Manufacturing Base and Competitors
Table 20. Seqirus Major Business
Table 21. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 22. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 24. Merck Sharp & Dohme Corp Major Business
Table 25. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 26. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Astellas Pharma US Basic Information, Manufacturing Base and Competitors
Table 28. Astellas Pharma US Major Business
Table 29. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 30. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 32. Pfizer Inc Major Business
Table 33. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 34. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 38. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 40. Lanzhou Institute of Biological Products Co., Ltd Major Business
Table 41. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 42. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 44. AstraZeneca Major Business
Table 45. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 46. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Emergent BioSolutions Inc Basic Information, Manufacturing Base and Competitors
Table 48. Emergent BioSolutions Inc Major Business
Table 49. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 50. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Company, (K Doses): 2020 VS 2021
Table 55. Head Office and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Site of Key Manufacturer
Table 56. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine New Entrant and Capacity Expansion Plans
Table 57. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Mergers & Acquisitions in the Past Five Years
Table 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 63. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 64. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 67. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2023-2028) & (USD/Dose)
Table 68. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 69. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 70. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 73. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2023-2028) & (USD/Dose)
Table 74. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 75. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 76. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 79. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 80. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 81. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 82. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 83. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 84. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 87. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 88. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 89. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 90. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 91. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 92. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 95. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 96. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 97. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 98. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 99. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 100. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 103. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 104. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 105. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 106. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 107. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 108. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 111. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 112. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 113. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 114. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Material
Table 115. Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Distributors
Table 119. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Customers
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 6. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 10. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Protein Sciences Corporation Basic Information, Manufacturing Base and Competitors
Table 12. Protein Sciences Corporation Major Business
Table 13. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 14. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 16. Novartis AG Major Business
Table 17. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 18. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Seqirus Basic Information, Manufacturing Base and Competitors
Table 20. Seqirus Major Business
Table 21. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 22. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 24. Merck Sharp & Dohme Corp Major Business
Table 25. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 26. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Astellas Pharma US Basic Information, Manufacturing Base and Competitors
Table 28. Astellas Pharma US Major Business
Table 29. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 30. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 32. Pfizer Inc Major Business
Table 33. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 34. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 38. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 40. Lanzhou Institute of Biological Products Co., Ltd Major Business
Table 41. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 42. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 44. AstraZeneca Major Business
Table 45. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 46. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Emergent BioSolutions Inc Basic Information, Manufacturing Base and Competitors
Table 48. Emergent BioSolutions Inc Major Business
Table 49. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 50. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Company, (K Doses): 2020 VS 2021
Table 55. Head Office and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Site of Key Manufacturer
Table 56. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine New Entrant and Capacity Expansion Plans
Table 57. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Mergers & Acquisitions in the Past Five Years
Table 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 63. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 64. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 67. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2023-2028) & (USD/Dose)
Table 68. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 69. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 70. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 73. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2023-2028) & (USD/Dose)
Table 74. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 75. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 76. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 79. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 80. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 81. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 82. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 83. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 84. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 87. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 88. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 89. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 90. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 91. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 92. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 95. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 96. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 97. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 98. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 99. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2023-2028) & (K Doses)
Table 100. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 103. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 104. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 105. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 106. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 107. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2023-2028) & (K Doses)
Table 108. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 111. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2023-2028) & (K Doses)
Table 112. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 113. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2023-2028) & (K Doses)
Table 114. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Material
Table 115. Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Distributors
Table 119. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type in 2021
Figure 3. Immune DTaP Vaccine
Figure 4. Therapy DTaP Vaccine
Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application in 2021
Figure 6. Adult
Figure 7. Pediatric
Figure 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2017-2028) & (K Doses)
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2017-2028) & (USD/Dose)
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity (2017-2028) & (K Doses)
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Figure 15. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Figure 16. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturer in 2021
Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturer in 2021
Figure 19. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 24. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 25. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028) & (USD/Dose)
Figure 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 35. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 36. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 38. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 39. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 46. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 55. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 62. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 63. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 64. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 77. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type in 2021
Figure 3. Immune DTaP Vaccine
Figure 4. Therapy DTaP Vaccine
Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application in 2021
Figure 6. Adult
Figure 7. Pediatric
Figure 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2017-2028) & (K Doses)
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2017-2028) & (USD/Dose)
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity (2017-2028) & (K Doses)
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Figure 15. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Figure 16. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturer in 2021
Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturer in 2021
Figure 19. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 24. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 25. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028) & (USD/Dose)
Figure 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 35. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 36. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 38. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 39. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 46. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 55. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 62. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 63. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2028)
Figure 64. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 77. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
